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 Clinical Observations with AN-1792 
Using TAPIR Analyses  
 Christoph Hock    Roger M. Nitsch  
 Division of Psychiatry Research, University of Zurich,  Zurich , Switzerland 
2 study the public awareness was drawn to the occurrence 
of severe side effects in the form of aseptic meningoen-
cephalitis in 6% of the patients on active vaccine. As a 
consequence, active dosing of the vaccine was halted, and 
further development was put on hold. Much criticism and 
pressure was put on the clinical investigators and also on 
the supporters of the amyloid cascade hypothesis. Seem-
ingly, an exciting scientiﬁ c and treatment opportunity had 
been about to get lost, but meticulous biological analyses 
and long-term clinical follow-up of the immunized patients 
ultimately revealed remarkable indications for efﬁ cacy and 
proof of concept – even after the occurrence of meningo-
encephalitis in individual patients. We brieﬂ y summarize 
here how the proof of concept was established and why it 
provides the basis for a potential cure for AD ( table 1 ). 
 Generation of Antibodies against   -Amyloid 
Plaques in Patients with AD 
 The formulation of the ﬁ rst active vaccine against   -
amyloid was composed of preaggregated, ﬁ brillar, syn-
thetic A   42  peptides combined with QS-21 as an adjuvant. 
It was termed AN-1792. A clinical safety and tolerability 
phase 1 study was done, with single and multiple dosing 
of AN-1792 in AD patients, and immunogenicity was as-
sessed in this trial as well  [3] . The study was followed by 
a phase 2 multicenter trial in 372 patients to assess safety, 
tolerability and pilot efﬁ cacy of AN-1792  [4] . Within the 
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 Abstract 
 Clinical observations with AN-1792 using  tissue amyloid 
plaque immunoreactivity (TAPIR) analyses established 
for the fi rst time evidence in humans that antibodies 
against    -amyloid-related epitopes are capable of slow-
ing progression in Alzheimer’s disease. Antibodies de-
rived upon TAPIR assay selection may specifi cally target 
the pathologic neoepitopes of aggregated A  species 
present in amyloid plaques and some of their aggregat-
ed, protofi brillar and low molecular weight oligomeric 
precursors. We briefl y summarize here how the proof of 
concept was established and why it provides the basis 
for a potential cure for Alzheimer’s disease. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The ﬁ rst immunization therapy of Alzheimer’s disease 
(AD) which entered clinical study phases 1 and 2 in 2000 
and 2001 was loaded with high expectations, since the pre-
vious experiments in transgenic mice had shown removal 
of brain   -amyloid plaques accompanied by functional res-
toration  [1, 2] . However, soon after the start of the phase 
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phase 2 study, we investigated a cohort of 30 patients in 
Zurich. We analyzed both the quality and the titers of an-
tibodies against   -amyloid plaques generated in response 
to the vaccination. To analyze antibodies against patho-
logically relevant   -amyloid-related structures, we devel-
oped the tissue amyloid plaque immunoreactivity 
(TAPIR) assay. It enabled us to identify and to quantitate 
antibodies that are not always detected by conventional 
ELISAs. In contrast to ELISAs, with immobilized prepa-
rations of pure synthetic peptides, the TAPIR assay uses 
bona ﬁ de tissue   -amyloid plaques that had been depos-
ited in vivo in living brains, that had been developing 
slowly over a long period of time, in close contact to neu-
ropil proteins as well as with neurite membranes, reactive 
astrocytes and activated glial cells. We expected that these 
conditions would allow for the detection with high sensi-
tivity of pathologically relevant, aggregated A  species 
neoepitope conformations including low molecular weight 
oligomers, protoﬁ brils and ﬁ brils. If low molecular weight 
oligomers, protoﬁ brils and ﬁ brils are relevant immuno-
therapeutic targets, TAPIR assays should be suitable for 
detecting biologically relevant immune responses. In fact, 
we found signiﬁ cant increases in serum titers of TAPIR-
positive antibodies in the vast majority of the 30 patients 
in the Zurich subcohort of the phase 2 AN-1792 trial  [5] . 
In line with our considerations, this group of patients was 
not identical to the group of patients with increased ELISA 
titers: Several patients in the Zurich cohort had increases 
in TAPIR-positive antibodies in the absence of an ELISA-
positive immune response, and vice versa, pointing to the 
difference in epitopes presented by ELISAs versus TAPIR 
assays  [6] . Since studies in transgenic mice had raised the 
possibility of antibody passage from blood to brain over 
the blood brain barrier  [7] , we analyzed CSF samples ob-
tained before and after immunization and found that the 
TAPIR-positive IgG antibodies were indeed present in 
CSF. This was true for CSF obtained from patients both 
with and without signs of blood-brain barrier dysfunction. 
Thus we showed that antibodies against   -amyloid-
 related epitopes were able to cross the blood-brain barrier 
and, presumably, reached the therapeutic targets in the 
brain. The mechanisms for blood-brain barrier passage of 
plasma-derived IgG are incompletely understood. They 
may include increased blood-brain barrier permeability, 
possibly related to disease- or vaccination-induced in-
ﬂ ammatory responses, passive diffusion, and active shut-
tling, possibly via F cN -mediated transcytosis. 
 Antibodies against   -Amyloid-Related 
Epitopes Slowed AD Progression 
 To explore the predictive value of antibody generation 
on the clinical outcome over time, we analyzed the Zurich 
subcohort of 30 patients using the TAPIR assay in serum 
pre- and postimmunization. We found that both cogni-
tive functions and capacities of daily living declined less 
in patients with increased serum titers of TAPIR-positive 
antibodies as compared to patients without such antibod-
ies  [6] . Moreover, there was a correlation of the antibody 
titers with clinical outcome. Patients with higher TAPIR 
scores showed better clinical performance over time, and 
the group of patients with the highest TAPIR scores re-
mained cognitively and functionally (on the basis of dai-
ly living capacities, DAD scale) stable for the entire ob-
servation period of 1 year. Interestingly, the titers of an-
tibodies also remained increased throughout this time 
period. Interestingly, the clinical analysis of the phase 1 
study in 80 patients also indicated positive effects on the 
level of daily living capacities as measured by the DAD 
scale  [3] . The clinical analyses of the multicenter cohort 
of 372 patients conﬁ rmed our observations by demon-
strating better performance of antibody responders iden-
tiﬁ ed by peptide-based ELISAs in a number of neuropsy-
Rationale in mice Rationale in humans Limitations
Reduction in amyloid 
plaques
Indications for reduced
amyloid plaque load
Aseptic meningoencephalitis 
in humans
Restoration of memory Better memory over time Microhemorrhages in some 
transgenic mouse models
Microglial phagocytosis 
of amyloid
Indications for microglial
phagocytosis of amyloid
Limited antibody responder 
rate
Indications for restoration
of hippocampal volumes
Balancing of B cell versus T 
cell response
Table 1. Active -amyloid immunization 
status
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chological test batteries  [4] . TAPIR analyses done in the 
entire cohort of 372 patients yielded similar results, thus 
conﬁ rming the positive effects of   -amyloid immuniza-
tion on memory performance in patients with AD [Hock, 
et al., in preparation]. Together, these clinical analyses of 
the ﬁ rst studies using   -amyloid immunization suggest 
that antibodies against   -amyloid-related epitopes are ef-
fective in slowing progression of dementia in AD. 
 Neuropathological Indications for   -Amyloid 
Removal from Brain 
 Neuropathological investigations of 3 patients immu-
nized with AN-1792 showed reduced   -amyloid pathology 
in extended brain areas along with lowered astrogliosis, 
while presence of neuroﬁ brillary tangles appeared to be 
preserved  [8–10] . Importantly, removal of   -amyloid was 
observed both in presence and absence of prior episodes 
of meningoencephalitis or signs of T cell inﬁ ltration of the 
brain. These ﬁ ndings suggest that meningoencephalitis is 
not required for   -amyloid removal. The presence of mi-
croglia ﬁ lled with   -amyloid in brain areas that have been 
cleared from   -amyloid following immunotherapy indi-
cated that phagocytosis of   -amyloid by microglial cells 
may constitute an important mechanism of plaque remov-
al from brain  [8, 10] . Additional mechanisms may include 
peripheral amyloid sink and antibody-mediated disaggre-
gation which may ﬁ nally add to amyloid clearance. 
 Effects of Antibodies against   -Amyloid-
Related Epitopes on Hippocampal Volumes 
Measured by MRI 
 MRI-based analysis of brain volumes revealed interest-
ing longitudinal changes which were different in patients 
with antibodies against   -amyloid-related epitopes and 
those without such antibodies. Fox et al.  [11] analyzed the 
multicenter cohort and observed a stronger decrease in 
brain volumes including the hippocampus in patients 
with antibody response as compared to patients without 
antibody response within 1 year of observation. This ﬁ nd-
ing was interpreted as an effect of lowered   -amyloid 
plaque load and reduced inﬂ ammation and astrogliosis. 
In our own independent analysis of the Zurich cohort of 
30 patients we also observed the greater hippocampal vol-
ume loss in patients with antibodies against   -amyloid 
during the ﬁ rst year of clinical observation, as compared 
to patients without such antibodies. In contrast to the mul-
ticenter cohort, however, we continued the clinical follow-
up investigations including the MRI scanning over a pe-
riod of 2 years. During the second year of clinical follow-
up the hippocampal volumes restored in the patients with 
antibodies against   -amyloid-related epitopes and re-
turned close to the baseline volumes [Hock et al., in prep-
aration]. In contrast, the hippocampal volumes in patients 
without antibodies against   -amyloid-related epitopes 
continued to decrease at the expected rate of roughly 3% 
per year. These results raise the fascinating speculation of 
a biphasic process of regeneration; ﬁ rst, an initial volume 
loss reﬂ ecting   -amyloid plaque removal and concurrent 
loss in astrocyte activation; second, a phase of structural 
build-up and volume restoration as signs for recovery and 
regeneration. Combined with MRI volumetry, amyloid 
PET imaging will allow for addressing this possibility dur-
ing the upcoming clinical immunotherapy trials  [12] . 
 Conclusions 
 Clinical observations with AN-1792 using TAPIR 
analyses established for the ﬁ rst time evidence in humans 
that antibodies against   -amyloid-related epitopes are ca-
pable of slowing AD progression. Antibodies derived 
upon TAPIR selection may speciﬁ cally target the patho-
logic neoepitopes of aggregated A  species present in am-
yloid plaques and some of their aggregated, protoﬁ brillar 
and low molecular weight oligomeric precursors. Thus, 
such antibodies may speciﬁ cally reduce the neurotoxicity 
related to neoepitope formation. Since the formation of 
abnormally aggregated A  species occurs early in the dis-
ease process leading to AD, prevention of its formation 
or its removal may be expected to result in the slowing or 
the prevention of neurodegeneration. Possibly, the suc-
cessful reduction in A  -related toxicity may also amelio-
rate such down-stream effects as inﬂ ammation, oxidative 
stress, cytoskeletal abnormalities, the formation of neu-
roﬁ brillary tangles, synaptic dysfunction, deﬁ cits in neu-
rotransmission and homeostasis of ions and metabolism. 
If clinical safety and tolerability can be improved, the col-
lected evidence reported here supports strongly that im-
munotherapy directed against toxic A  species in brains 
holds the promise of a future cure for AD. 
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